High HIF-1 alpha expression predicts poor prognosis of patients with colon adenocarcinoma
High HIF-1 alpha expression predicts poor prognosis of patients with colon adenocarcinoma
复制标题
HIF-1α高表达预示结肠腺癌患者预后不良
DOI：
--
复制
发表时间：
2018
影响因子：
1.4
通讯作者：
Gao Jin-Hang
中科院分区：
文献类型：
--
作者：
Huang Zhi-Yin;Zhang Lin-Hao;Zhao Chong;Liu Rui;Tong Huan;Gan Can;Lan Tian;Tang Cheng-Wei;Gao Jin-Hang
低氧诱导因子1 α亚基（HIF-1 α）在低氧条件下被诱导，并且在肿瘤的新生血管生成和转移中起关键作用。本研究旨在检测结肠腺癌组织中HIF-1 α的表达，探讨结肠腺癌的临床病理特征及预后。采用组织芯片技术检测92例结肠腺癌及其癌旁组织中HIF-1 α的表达。结肠腺癌组织中HIF-1 α的表达明显高于癌旁组织（P < 0.001）。HCT 116和RKO人结肠癌裸鼠移植瘤的免疫组化结果相似（P < 0.05）。此外，HIF-1 α表达增强与TNM分期III-IV（P = 0.025）、远处转移和血管浸润（P = 0.048）以及阳性淋巴结（P = 0.041）呈正相关。Kaplan-Meier生存分析显示，HIF-1 α表达上调与5年或10年生存率相关（P < 0.05）。多因素考克斯回归分析也发现HIF-1 α是结肠腺癌预后不良的独立危险因素。因此，靶向HIF-1 α可能是治疗结肠腺癌患者的可行策略。
Hypoxia inducible factor 1 alpha subunit (HIF-1 alpha) is induced in hypoxic conditions and plays a crucial role in the neoangiogenesis and metastasis of cancer. In this study, we aimed to evaluate the expression of HIF-1 alpha in colon adenocarcinoma and to explore its clinicopathological characteristics and prognosis. A tissue microarray involving colon adenocarcinoma tissues and their corresponding paracancerous tissues from 92 patients was utilized to detect HIF-1 alpha. The expression of HIF-1 alpha in colon adenocarcinoma tissues was significantly higher than it was in the corresponding paracancerous tissues (P < 0.001). Furthermore, similar results were observed in HCT116 and RKO human colon adenocarcinoma xenografts in node mice (P < 0.05). Additionally, augmented HIF-1 alpha expression was positively associated with TNM stage III-IV (P = 0.025), the presence of distant metastasis and vascular invasion (P = 0.048), and the presence of positive lymph nodes (P = 0.041). A Kaplan-Meier survival analysis showed that up-regulation of HIF-1 alpha was associated with poor 5-year or 10-year survival (P < 0.05). A multivariable Cox regression analysis also found HIF-1 alpha was an independent risk factor for poor prognosis in colon adenocarcinoma. Thus, targeting HIF-1 alpha might be a viable strategy to treat patients with colon adenocarcinoma.